

Comments from Mattias Perjos, CEO

Organic growth, strong cash flow and regulatory milestone

"We succeeded in surpassing last year's record-breaking first quarter with organic growth in both order intake and net sales. This was despite a decline for Acute Care Therapies, primarily in ventilators, where we were highly active last year and captured shares in the wake of market consolidation. Consumables for life-supporting ECLS therapy continued to show stable growth from a leading position globally. Surgical Workflows reported a double-digit increase in its order intake following strong growth in all product categories, where equipment for operating rooms in the US particularly contributed. Life Science also noted a strong start to the year with organic sales growth of a full 16%. The overall order intake was positive but varied within the business area. The investment climate for pharma is impacted by the geopolitical uncertainty, which is primarily seen in the order intake for the project-based and capital intense product category WIS.

Adjusted EBITA margin was 11.1%, and excluding tariffs and currency effects would have been 12.6% and thus an underlying improvement on last year. This confirms the ongoing positive trend in structural profitability thanks to a steady focus on price adjustments, productivity and cost control. This is also reflected in the strong cash flow in the quarter.

We expanded the product portfolio in Life Science with a new steam sterilizer, designed for laboratory and research applications. Furthermore, an important regulatory milestone was achieved at the end of the quarter with the receipt of the CE mark for Cardiohelp II, a brand-new generation of ECLS systems. The product is developed in close collaboration with our customers and is even more user-friendly and mobile. In cardiovascular surgery, the Intergard Synergy antimicrobial vascular graft also received EU MDR approval.

We are continuing to demonstrate that we are well positioned in the prioritized product categories of our customers, which gives us confidence for the future. There is currently high geopolitical uncertainty, however, based on dialogue with our customers, we choose to maintain our forecast of organic sales growth of 3–5% in 2026."

January – March 2026 in brief

- Net sales increased organically by 0.8% (6.2) and the order intake rose by 3.9% organically (2.9)
- Adjusted gross profit amounted to SEK 3,828 M (4,337) and the margin was 51.4% (52.1)
- Adjusted EBITA was SEK 824 M (1,003) and the margin 11.1% (12.1)
- Adjusted earnings per share amounted to SEK 1.80 (2.18)
- Free cash flow amounted to SEK 842 M (160)

Outlook 2026: Net sales for 2026 are expected to increase by 3–5% organically, adjusted for the phase-out of Surgical Perfusion¹⁾ (Unchanged)

Summary of financial performance²⁾

SEK M	Jan-Mar 2026	Jan-Mar 2025	R12 Mar 2026	Jan-Dec 2025
Order intake	7,939	8,632	33,331	34,025
<i>Organic change, %</i>	3.9	2.9		3.5
Net sales	7,443	8,320	34,092	34,969
<i>Organic change, %</i>	0.8	6.2		4.9
Adjusted gross profit	3,828	4,337	17,099	17,607
<i>Margin, %</i>	51.4	52.1	50.2	50.4
Adjusted EBITDA	1,222	1,442	6,361	6,581
<i>Margin, %</i>	16.4	17.3	18.7	18.8
Adjusted EBITA	824	1,003	4,701	4,880
<i>Margin, %</i>	11.1	12.1	13.8	14.0
Adjusted EBIT	738	896	4,335	4,494
<i>Margin, %</i>	9.9	10.8	12.7	12.9
Operating profit (EBIT)	707	598	3,898	3,789
<i>Margin, %</i>	9.5	7.2	11.4	10.8
Profit before tax	573	428	3,290	3,145
Net profit for the period	402	304	2,374	2,276
Adjusted net profit for the period	490	597	2,986	3,093
<i>Margin, %</i>	6.6	7.2	8.8	8.8
Adjusted earnings per share, SEK	1.80	2.18	10.91	11.29
Earnings per share, SEK	1.47	1.10	8.66	8.29
Cash flow from operating activities	1,106	470	4,585	3,949
Free cash flow	842	160	3,334	2,652

¹⁾ For more information about the adjustment of the Organic change key ratio, refer to Other information on page 9

²⁾ See page 3 for calculations of adjusted performance measures

- The organic order intake for Acute Care Therapies declined, mainly within ventilation where we last year had temporarily increased volumes due to market consolidation. At the same time, growth in ECLS therapy consumables was strong.
- Life Science's organic order intake increased during the quarter, partly due to recovery in Bio-Processing. WIS decreased as a result of geopolitical uncertainty and the continued challenging investment climate for pharma.
- Surgical Workflows reported a double-digit increase in organic order intake following a strong trend in all product categories.
- Geographically, the organic order intake trend was positive in all regions.

- Net sales for Acute Care Therapies decreased organically, mainly due to the above-mentioned reason in ventilation. Sales of ECLS therapy consumables also increased.
- Organic net sales for Life Science grew double-digit after growth in all product categories, with Sterile Transfer contributing the most.
- In Surgical Workflows, organic net sales rose following growth in primarily consumables and service in Infection Control and operating tables in Surgical Workplaces.
- Positive organic growth in EMEA, including strong performances in Italy and Germany. Sales declined in Americas and APAC
- Recurring revenues increased in the quarter following growth in, for example, Sterile Transfer and ECLS therapy. Sales of capital goods declined in the quarter, mainly due to Critical Care and Cardiac Assist.

- Net sales declined by SEK 877 M, corresponding to -10.5%.
- Exchange rates had an impact of SEK -901 M on sales, corresponding to -10.8%.
- Successful efforts with price adjustments and volumes had an impact of SEK +66 M on sales, corresponding to +0.8%.

Group performance

Order intake

Order intake business areas, SEK M	Jan-Mar 2026	Jan-Mar 2025	Org Δ, %	R12 Mar 2026	Jan-Dec 2025
Acute Care Therapies	4,256	4,924	-1.2	17,552	18,220
Life Science	908	978	2.9	4,182	4,252
Surgical Workflows	2,774	2,730	13.3	11,597	11,553
Total	7,939	8,632	3.9	33,331	34,025

Order intake regions, SEK M	Jan-Mar 2026	Jan-Mar 2025	Org Δ, %	R12 Mar 2026	Jan-Dec 2025
Americas	3,680	4,085	4.4	15,024	15,429
APAC	1,407	1,531	6.0	6,187	6,311
EMEA	2,852	3,017	2.2	12,121	12,285
Total	7,939	8,632	3.9	33,331	34,025

Net sales


Net sales business areas, SEK M	Jan-Mar 2026	Jan-Mar 2025	Org Δ, %	R12 Mar 2026	Jan-Dec 2025
Acute Care Therapies	4,012	4,775	-4.0	17,913	18,675
Life Science	1,003	950	16.0	4,551	4,498
Surgical Workflows	2,428	2,595	4.0	11,629	11,796
Total	7,443	8,320	0.8	34,092	34,969

Net sales regions, SEK M	Jan-Mar 2026	Jan-Mar 2025	Org Δ, %	R12 Mar 2026	Jan-Dec 2025
Americas	3,453	4,047	-1.1	15,091	15,686
APAC	1,355	1,642	-5.0	6,656	6,943
EMEA	2,635	2,630	7.4	12,345	12,340
Total	7,443	8,320	0.8	34,092	34,969

Net sales specified by capital goods and recurring revenue, SEK M	Jan-Mar 2026	Jan-Mar 2025	Org Δ, %	R12 Mar 2026	Jan-Dec 2025
Capital goods	2,078	2,481	-6.8	11,565	11,968
Recurring revenue ¹⁾	5,365	5,839	4.0	22,527	23,001
Total	7,443	8,320	0.8	34,092	34,969

1) Consumables, service and spare parts

Net sales – bridge between Q1 2025 and Q1 2026



Earnings trend

- Currency effects impacted adjusted gross profit by SEK -543 M and adjusted EBITA by SEK -122 M compared with last year.
- The gross margin declined, mainly due to lower sales, negative currency effects and tariff costs.
- Adjusted EBITA fell by SEK 179 M, of which tariff costs had an impact of SEK -104 M and currency effects of SEK -122 M compared with last year. Despite continued successful price adjustments and positive mix, the margin declined 1.0 percentage point.
- Acquisition and restructuring costs are primarily related to the ongoing rationalizations in the organization.
- Net financial items decreased to SEK -135 M, mainly as a result of lower average interest year-on-year.
- The tax rate at the end of the quarter was 29.7%.

SEK M	Jan-Mar 2026	Jan-Mar 2025	R12 Mar 2026	Jan-Dec 2025
Net sales	7,443	8,320	34,092	34,969
Adjusted gross profit	3,828	4,337	17,099	17,607
Margin, %	51.4	52.1	50.2	50.4
Adjusted operating expenses	-2,607	-2,895	-10,737	-11,026
Adjusted EBITDA	1,222	1,442	6,361	6,581
Margin, %	16.4	17.3	18.7	18.8
Depreciation, amortization and write-downs of intangible assets and tangible assets ¹⁾	-397	-439	-1,660	-1,702
Adjusted EBITA	824	1,003	4,701	4,880
Margin, %	11.1	12.1	13.8	14.0
A Amortization and write-down of acquired intangible assets ¹⁾	-87	-107	-366	-386
Adjusted EBIT	738	896	4,335	4,494
Margin, %	9.9	10.8	12.7	12.9
B Acquisition and restructuring costs	-30	-298	-130	-397
C Other items affecting comparability ²⁾	-	-	-307	-307
Operating profit (EBIT)	707	598	3,898	3,789
Net financial items	-135	-170	-608	-644
Profit before tax	573	428	3,290	3,145
Adjusted profit before tax (adjusted for A, B and C)	690	833	4,093	4,236
Margin, %	9.3	10.0	12.0	12.1
Taxes	-170	-124	-916	-869
D Tax on adjustment items ²⁾	-29	-112	-191	-273
Adjusted net profit for the period (adjusted for A, B, C and D)	490	597	2,986	3,093
Margin, %	6.6	7.2	8.8	8.8
Of which, attributable to Parent Company shareholders	489	593	2,972	3,076
Average number of shares, thousands	272,370	272,370	272,370	272,370
Adjusted earnings per share, SEK (adjusted for A, B, C and D)	1.80	2.18	10.91	11.29

1) Excluding items affecting comparability (see Note 4 Depreciation, amortization and write-downs)

2) See Note 6 Adjustment items


Adjusted EBITA per business area¹⁾

- Adjusted EBITA for Acute Care Therapies declined by SEK 249 M, mainly due to negative currency and tariff effects as well as lower sales. This was despite continued successful price adjustments and a favorable mix. The margin fell by 2.2 percentage points.
- Life Science's adjusted EBITA increased by SEK 43 M, mainly due to price adjustments and higher sales volumes. The margin improved by 1.2 percentage points.
- Costs in Group functions and other were largely unchanged year-on-year.

SEK M	Jan-Mar 2026	Jan-Mar 2025	R12 Mar 2026	Jan-Dec 2025
Acute Care Therapies	763	1,012	3,514	3,763
Margin, %	19.0	21.2	19.6	20.2
Life Science	96	53	533	490
Margin, %	9.6	5.5	11.7	10.9
Surgical Workflows	75	49	1,104	1,077
Margin, %	3.1	1.9	9.5	9.1
Group functions and other (incl. eliminations)	-110	-110	-450	-450
Total	824	1,003	4,701	4,880
Margin, %	11.1	12.1	13.8	14.0

1) See Note 4 Depreciation, amortization and write-downs and Note 6 Adjustment items for other items affecting comparability

Adjusted EBITA – bridge between Q1 2025 and Q1 2026



- Adjusted operating expenses for selling and administration fell by 6.8%. Organically they increased by 3.0%, mainly due to higher sales activities.
- The year-on-year difference for other operating income and expenses was mainly attributable to currency effects related to operating receivables and liabilities in foreign currency.

- Costs for R&D were 2.9% lower year-on-year.
- Capitalized development costs were 11.9% lower compared with last year.
- The year-on-year difference was mainly due to lower costs for quality-related efforts.
- Amortization and write-down of capitalized development costs amounted to SEK -84 M (-100), whereof SEK 0 M write-down (0).

- Exchange-rate fluctuations, meaning translation and transaction effects, impacted adjusted gross profit by SEK -543 M compared with last year, of which SEK -395 M in translation effects and SEK -148 M in transaction effects.
- The change in adjusted EBITA attributable to currency effects was SEK -122 M, of which SEK -97 M arose from translation effects and SEK -25 M from the net of transaction effects, and revaluation of operating receivables and liabilities in foreign currency.

- Compared with last year, free cash flow was positively impacted by operating profit and changes in working capital, mainly due to changes in inventories and accounts payable.
- The financial position remains solid.

Adjusted operating expenses

(excluding depreciation, amortization and write-downs and other items affecting comparability)¹⁾

	Jan-Mar 2026	Jan-Mar 2025	R12 Mar 2026	Jan-Dec 2025
SEK M				
Selling expenses	-1,277	-1,404	-5,217	-5,345
Administrative expenses	-1,034	-1,075	-4,141	-4,182
Selling and administrative expenses	-2,311	-2,479	-9,358	-9,527
Research and development costs	-308	-301	-1,252	-1,244
Other operating income and expenses	12	-115	-127	-255
Total	-2,607	-2,895	-10,737	-11,026

1) See Note 4 Depreciation, amortization and write-downs and Note 6 Adjustment items for other items affecting comparability

Research and development

	Jan-Mar 2026	Jan-Mar 2025	R12 Mar 2026	Jan-Dec 2025
SEK M				
Research and development costs	-463	-477	-1,907	-1,921
Amortization, depreciation and write-downs	-19	-17	-177	-175
Research and development costs, gross	-482	-494	-2,085	-2,096
<i>In relation to net sales, %</i>	6.5	5.9	6.1	6.0
Capitalized development costs	155	176	622	643
<i>In relation to net sales, %</i>	2.1	2.1	1.8	1.8
Research and development costs, net	-328	-318	-1,462	-1,452
Amortization and write-down of capitalized development costs¹⁾	-84	-100	-414	-430

1) Capitalized development projects

Currency impact

	Jan-Mar 2026	R12 Mar 2026
SEK M		
Net sales	-901	-3,200
Adjusted gross profit	-543	-1,833
Adjusted EBITDA	-153	-840
Adjusted EBITA	-122	-724
Adjusted EBIT	-108	-690

Cash flow and financial position¹⁾

	Jan-Mar 2026	Jan-Mar 2025	R12 Mar 2026	Jan-Dec 2025
SEK M				
Cash flow before changes in working capital	864	1,132	4,869	5,137
Changes in working capital	242	-662	-284	-1,188
Net investments in non-current assets	-264	-310	-1,251	-1,297
Free cash flow	842	160	3,334	2,652
Net interest-bearing cash/debt	9,268	9,731	9,268	9,840
<i>In relation to adjusted EBITDA¹⁾ R12M, multiple</i>	1.5	1.4	1.5	1.5
Net interest-bearing cash/debt, excl. pension provisions	6,968	7,279	6,968	7,482
<i>In relation to adjusted EBITDA¹⁾ R12M, multiple</i>	1.1	1.1	1.1	1.1

1) See Note 6 Adjustment items for items affecting comparability and Note 8 for alternative performance measures

Sustainability developments

This interim report reflects Getinge's double materiality assessment and is based on the ESRS structure to present the company's impact, risks and opportunities from a social, environmental and governance perspective. The aim is to continuously work to minimize the negative impact on people and the environment and to generate sustainable value for customers, employees and other stakeholders.

- Getinge's energy efficiency measures are continuing to yield results in terms of both energy consumption and lower Scope 1 & 2 emissions from production facilities. The increase in the share of renewable electricity and gas in the first quarter also generated positive effects in the form of reduced emissions.
- Water consumption is mainly related to testing in production and therefore varies over time. The rising trend in the outcome for R12 March 2026 was due to increased production activity and an identified and repaired leak at one of Getinge's facilities.
- The Work Related Accident Rate (WRAR) continued to show a positive trend in the outcome for R12 March 2026.
- From 2026, the definition of the regulatory compliance KPI has been revised to focus on major observations from regulators and notified bodies only. Consequently, the regulatory compliance target has been updated from ≤ 1.5 audit findings to ≤ 1.2 audit findings.
- From 2026, the KPI for training in business ethics represents the percentage of employees who completed Getinge's new Code of Conduct workshop. Accordingly, the outcome represents only Jan-Mar 2026. The target remains that all employees are properly trained in business ethics.

Key areas	R12 Mar 2026 ¹⁾	R12 Mar 2025 ¹⁾	Δ , % ²⁾	Jan-Dec 2025	Δ , % ³⁾
Environment, Climate & Energy					
Scope 1 & 2 GHG emissions in production, ton CO ₂ equivalents ⁹⁾	4,708	5,310	-11.3	4,913	-4.2
Total energy consumption in production, MWh ⁹⁾	79,674	82,341	-3.2	80,887	-1.5
Percentage of renewable energy of total energy, % ⁹⁾	70	67	3.0*	69	1.0*
Water consumption in sites located in water scarce areas, m ⁴ , ⁹⁾	120,719	102,376	17.9	114,691	5.3
Social					
Own workforce					
Employee engagement, % ⁵⁾	73	71	2.0*	73	0.0*
Percentage of female employees, % ⁶⁾	38.4	37.7	0.7*	38.2	0.2*
Percentage of female managers, % ⁶⁾	34.8	34.3	0.5*	34.1	0.7*
Work Related Accident Rate, WRAR ⁹⁾	0.48	0.95	-0.5	0.59	-0.1
Consumers and end-users					
Regulatory compliance, audit findings per audit for quality systems ⁷⁾	0.8	-	-	0.7	9.6
Product quality, field actions per SEK billion in net revenue	0.8	1.3	-36.9	1.0	-15.5
Online customer training	52,525	49,951	5.2	53,238	-1.3
Governance					
Business ethics					
Percentage of employees who completed training in business ethics, % ⁸⁾	49	-	-	-	-

*) Change in percentage points

1) R12 = Rolling 12 months

2) Index R12 Mar 2026/ R12 Mar 2025

3) Index R12 Mar 2026/ Jan-Dec 2025

4) The production sites in scope are those located in areas with high or extremely high water stress according to the WRI Water Risk Atlas tool Acqueduct, which are eight sites. One of these sites was incorrectly stated in Getinge's 2025 Sustainability Report as being located in Rastatt, Germany. The correct location is Hechingen, Germany



5) Measured and updated every six months

6) Amount at end of period

7) Data available from 2025. According to the previous definition of the KPI, the outcome was 1.4 audit findings for the full-year 2025

8) Outcome for Jan-Mar 2026. The outcome for the previous training in business ethics was 92% for the full-year 2025

9) Four legal entities, Healthmark, Ultra Clean, Quadralene and Paragonix, joined the Group by acquisition, and data was updated in 2025. See Getinge's Annual Report 2025 for more information



— Total energy consumption in production, MWh
 ■ Scope 1 & 2 GHG emissions in production, ton CO₂ equivalents

■ Product quality, field actions per SEK billion in net revenue

Acute Care Therapies

Acute Care Therapies offers world-leading solutions for life support in acute health conditions. The offering includes solutions for cardiovascular procedures, efficient handling of organs for transplantation and a broad selection of products and therapies for intensive care.

- The organic order intake for Acute Care Therapies declined, mainly within ventilation where we last year had temporarily increased volumes due to market consolidation. At the same time, growth in ECLS therapy consumables was strong.
- Geographically, the organic order intake increased strongly in APAC, with the main contributions from India and China. The decline in Americas was mainly attributable to market consolidation in ventilation in the US.

- Net sales for Acute Care Therapies decreased organically, mainly due to the above-mentioned reason in ventilation. Sales of ECLS therapy consumables also increased.
- Sales grew organically in EMEA following a particularly positive trend in ECLS therapy, anesthesia and ventilation. The decline in Americas was mainly attributable to market consolidation in ventilation in the US.
- Recurring revenue was largely unchanged, while sales of capital goods declined organically, mainly due to Critical Care and Cardiac Assist.

- The adjusted gross margin declined by 0.4 percentage points, largely due to negative currency and tariff effects as well as lower sales volumes.
- Adjusted selling and administrative expenses increased organically by 1.7%. Inorganically, these expenses fell by 8.9%.
- Adjusted EBITA for Acute Care Therapies declined by SEK 249 M, mainly due to negative currency and tariff effects as well as lower sales. This was despite continued successful price adjustments and a favorable mix. The margin fell by 2.2 percentage points.
- Currency effects impacted sales by SEK -531 M, adjusted gross profit by SEK -346 M and adjusted EBITA by SEK -93 M compared with last year.

Order intake and net sales

Order intake regions, SEK M	Jan-Mar 2026	Jan-Mar 2025	Org Δ, %	R12 Mar 2026	Jan-Dec 2025
Americas	2,197	2,747	-7.2	9,241	9,791
APAC	895	949	9.1	3,528	3,583
EMEA	1,165	1,228	4.5	4,783	4,846
Total	4,256	4,924	-7.2	17,552	18,220

Net sales regions, SEK M	Jan-Mar 2026	Jan-Mar 2025	Org Δ, %	R12 Mar 2026	Jan-Dec 2025
Americas	2,089	2,650	-8.5	9,331	9,893
APAC	848	1,024	-3.9	3,753	3,928
EMEA	1,076	1,101	7.0	4,829	4,854
Total	4,012	4,775	-4.0	17,913	18,675

Net sales specified by capital goods and recurring revenue, SEK M	Jan-Mar 2026	Jan-Mar 2025	Org Δ, %	R12 Mar 2026	Jan-Dec 2025
Capital goods	726	1,037	-20.2	3,956	4,267
Recurring revenue ¹⁾	3,287	3,737	0.5	13,957	14,407
Total	4,012	4,775	-4.0	17,913	18,675

¹⁾ Consumables, service and spare parts

Earnings trend¹⁾

SEK M	Jan-Mar 2026	Jan-Mar 2025	R12 Mar 2026	Jan-Dec 2025
Net sales	4,012	4,775	17,913	18,675
Adjusted gross profit	2,414	2,894	10,417	10,897
Margin, %	60.2	60.6	58.2	58.4
Adjusted EBITDA	962	1,236	4,341	4,616
Margin, %	24.0	25.9	24.2	24.7
Depreciation, amortization and write-downs of intangible assets and tangible assets	-199	-224	-827	-853
Adjusted EBITA	763	1,012	3,514	3,763
Margin, %	19.0	21.2	19.6	20.2

¹⁾ See Note 4 Depreciation, amortization and write-downs and Note 6 Adjustment items for other items affecting comparability

Events in the business area in the quarter

- A key milestone was achieved with receipt of the CE mark for Cardiohelp II, the next evolution of the transportable extracorporeal life support (ECLS) system.
- EU MDR certification for Intergard Synergy, a permanent antimicrobial vascular graft intended for replacement of arteries in the body. Intergard Synergy is a Drug Combination Device, coated two active substances, silver acetate and triclosan, to prevent risk of infection in relation to surgery.

Life Science

Life Science offers a comprehensive range of equipment, technical expertise and consultation to prevent contamination in pharmaceutical and medical device production and with the aim to strengthen integrity of results in biomedical research.

- Life Science's organic order intake increased during the quarter, mainly related to Nuclear and Bio-Processing. WIS decreased as a result of geopolitical uncertainty and the continued challenging investment climate for pharma.
- The organic order intake increased in Americas and APAC but declined in EMEA, mainly related to WIS.

- Organic net sales for Life Science grew double-digit after growth in all product categories, with Sterile Transfer contributing the most.
- Organic sales increased in all regions, with Sterile Transfer the main contributor in EMEA and APAC, while WIS was the main contributor in Americas.
- Recurring revenue and capital goods reported double-digit growth. Sterile Transfer contributed strongly to both categories, where sales of the hardware DPTE®-Alpha Port enables future sales of the consumable DPTE®-BetaBag.

- The adjusted gross margin declined by 1.8 percentage points, mainly due to negative currencies and tariff effects.
- Adjusted selling and administrative expenses increased organically by 1.7%. Inorganically, these expenses fell by -6.4%.
- Life Science's adjusted EBITA increased by SEK 44 M, mainly attributable to a favorable mix and price adjustments. The margin increased by 4.1 percentage points.
- Currency effects impacted sales by SEK -100 M, adjusted gross profit by SEK -57 M and adjusted EBITA by SEK -11 M compared with last year.

Order intake and net sales

Order intake regions, SEK M	Jan-Mar	Jan-Mar	Org Δ, %	R12 Mar	Jan-Dec
	2026	2025		2026	2025
Americas	358	336	23.6	1,492	1,469
APAC	138	108	45.5	550	520
EMEA	412	534	-18.7	2,141	2,263
Total	908	978	2.9	4,182	4,252

Net sales regions, SEK M	Jan-Mar	Jan-Mar	Org Δ, %	R12 Mar	Jan-Dec
	2026	2025		2026	2025
Americas	381	369	18.9	1,672	1,660
APAC	104	108	10.0	598	603
EMEA	518	473	15.1	2,280	2,235
Total	1,003	950	16.0	4,551	4,498

Net sales specified by capital goods and recurring revenue, SEK M	Jan-Mar	Jan-Mar	Org Δ, %	R12 Mar	Jan-Dec
	2026	2025		2026	2025
Capital goods	326	312	15.4	1,887	1,872
Recurring revenue ¹⁾	676	638	16.4	2,664	2,626
Total	1,003	950	16.0	4,551	4,498

1) Consumables, service and spare parts

Earnings trend¹⁾

SEK M	Jan-Mar	Jan-Mar	R12 Mar	Jan-Dec
	2026	2025	2026	2025
Net sales	1,003	950	4,551	4,498
Adjusted gross profit	377	374	1,679	1,676
Margin, %	37.6	39.4	36.9	37.3
Adjusted EBITDA	146	108	749	712
Margin, %	14.5	11.4	16.5	15.8
Depreciation, amortization and write-downs of intangible assets and tangible assets	-50	-56	-216	-222
Adjusted EBITA	96	53	533	490
Margin, %	9.6	5.5	11.7	10.9

1) See Note 4 Depreciation, amortization and write-downs and Note 6 Adjustment items for other items affecting comparability

Events in the business area in the quarter

- Getinge Lancer LSS 700 was launched, a new addition to Getinge's steam sterilizer series. Designed for use in laboratory and research facilities, the product offers a larger chamber to efficiently process high-capacity equipment such as bioreactors.

Surgical Workflows

Surgical Workflows offers products and solutions to serve as an end-to-end partner for optimizing the quality, safety and capacity usage of the sterile supply departments and operating rooms.

- Surgical Workflows reported a double-digit increase in organic order intake following a strong trend in all product categories.
- Growth was particularly strong in North America, mainly in consumables in Infection Control and operating room equipment in Surgical Workplaces.

- In Surgical Workflows, organic net sales rose following growth in primarily consumables and service in Infection Control and operating tables in Surgical Workplaces.
- Geographically, growth was high in Americas and EMEA. The volatile sales profile in Digital Health Solutions was the main reason for the decline in APAC.
- Growth in recurring revenue while capital goods declined, mainly in Infection Control.

- The adjusted gross margin increased by 1.6 percentage points, mainly attributable to continued successful price adjustments and higher sales volumes.
- Adjusted selling and administrative expenses increased organically by 5.4%, mainly as a result of higher sales activities. Inorganically, these expenses fell by 4.3%.
- Adjusted EBITA for Surgical Workflows increased by SEK 27 M, mainly due to price adjustments and higher sales volumes. The margin improved by 1.2 percentage points.
- Currency effects impacted sales by SEK -270 M, adjusted gross profit by SEK -140 M and adjusted EBITA by SEK -24 M compared with last year.

Order intake and net sales

Order intake regions, SEK M	Jan-Mar 2026	Jan-Mar 2025	Org Δ, %	R12 Mar 2026	Jan-Dec 2025
Americas	1,125	1,001	29.5	4,291	4,168
APAC	374	473	-9.4	2,109	2,208
EMEA	1,276	1,255	8.8	5,197	5,176
Total	2,774	2,730	13.3	11,597	11,553

Net sales regions, SEK M	Jan-Mar 2026	Jan-Mar 2025	Org Δ, %	R12 Mar 2026	Jan-Dec 2025
Americas	983	1,028	10.5	4,088	4,133
APAC	404	510	-10.3	2,305	2,412
EMEA	1,041	1,056	4.4	5,236	5,251
Total	2,428	2,595	4.0	11,629	11,796

Net sales specified by capital goods and recurring revenue, SEK M	Jan-Mar 2026	Jan-Mar 2025	Org Δ, %	R12 Mar 2026	Jan-Dec 2025
Capital goods	1,025	1,132	-0.7	5,722	5,829
Recurring revenue ¹⁾	1,402	1,463	7.6	5,907	5,967
Total	2,428	2,595	4.0	11,629	11,796

¹⁾ Consumables, service and spare parts

Earnings trend¹⁾

SEK M	Jan-Mar 2026	Jan-Mar 2025	R12 Mar 2026	Jan-Dec 2025
Net sales	2,428	2,595	11,629	11,796
Adjusted gross profit	1,037	1,068	5,002	5,034
<i>Margin, %</i>	42.7	41.2	43.0	42.7
Adjusted EBITDA	222	205	1,713	1,697
<i>Margin, %</i>	9.1	7.9	14.7	14.4
Depreciation, amortization and write-downs of intangible assets and tangible assets	-147	-157	-609	-619
Adjusted EBITA	75	49	1,104	1,077
<i>Margin, %</i>	3.1	1.9	9.5	9.1

¹⁾ See Note 4 Depreciation, amortization and write-downs and Note 6 Adjustment items for other items affecting comparability

Events in the business area in the quarter

- Product Area Digital Health Solutions grew order intake by more than 30% in the quarter. There was especially great momentum for the OR Integration product line with significant wins in the UK and Central Eastern Europe, which confirms the solid market success for the Matrix Tegriss system.

Other information

Events after the end of the reporting period

The geopolitical uncertainty and changing global environment continue to dominate the market. We are monitoring developments closely and continuously assessing the potential impact on our operations.

Seasonal variations

Getinge's sales and earnings are affected by seasonal variations. The highest net sales are usually generated in the fourth quarter, followed by the second, third and first quarters. The shares of sales derived from capital goods and recurring revenue also normally changes during the year, with a higher share of sales of capital goods toward the end of the year.

Transactions with related parties

Getinge carried out normal commercial transactions with companies in the Carl Bennet AB sphere, which comprised the sale and purchase of goods and services. In addition, no other significant transactions with related parties occurred during the period other than transactions with subsidiaries.

Forward-looking information

This report contains forward-looking information based on the current expectations of company management. Although management deems that the expectations presented by such forward-looking information are reasonable, no guarantee can be given that these expectations will prove correct. Accordingly, the actual future outcome could vary considerably compared with what is stated in the forward-looking information, due to such factors as changed conditions regarding finances, market and competition, changes in legal and regulatory requirements and other political measures, and fluctuations in exchange rates.

Update of Organic change key ratio

The definition of Organic change has been updated from the first quarter of 2026 to also adjust for phase-outs of product categories. The change has been made to provide a more fair presentation of underlying growth even when phase-outs are currently being made. Quarterly comparative figures for 2025, excluding the Surgical Perfusion product category, are published on Getinge's website under Reports and Presentations, <https://www.getinge.com/int/company/investors/reports-presentations/>.

Surgical Perfusion's sales in 2026 are expected to decline from approximately SEK 250 M to SEK 50 M.

Getinge's financial targets 2024–2028 and dividend policy

- Average adjusted earnings per share growth: >12%*
- Getinge's dividend policy is to pay dividends of 30-50% of net profit to shareholders.

Getinge's sustainability targets

Environment

- Reduce Scope 1 and 2 emissions by 90% by 2030**
- Reduce Scope 3 emissions by 25% by 2030, and by 90% by 2050**
- Reduce energy consumption in production by 20% by 2030**
- Reduce water consumption in sites located in water scarce areas by 20% by 2030**
- No waste to landfill by 2030, excluding material required by local regulations to be landfilled

Social

- Employee engagement: >70%

- Maintain work-related accidents in relation to working hours (Work Related Accident Rate, WRAR) at less than 1.
- Ensure equal employment opportunity and non-discrimination across all levels of the organization Follow-up % female vs male managers and employees
- Quality regulatory compliance, audit results/inspection: <1.2 deviation

Governance

- All employees are properly trained in Business ethics

**Base year 2023*

***Base year 2021*

Risk management

Risk management

Getinge operates in a global market and has a strong presence in a large number of countries. Active risk management at all levels is important in order for Getinge to successfully continue to create innovative products and services that improve people's quality of life.

Risk management framework

Getinge's three business areas and the Global Sales and Service organization are responsible for identifying and managing risks in their respective areas. The corporate and Group support functions support these units by providing governance, developing processes and promoting synergies in their specific areas of competence. In addition, several forums and groups have been established that focus on certain areas and identify and monitor specific types of risks.

Getinge has an Enterprise Risk Management (ERM) process covering all business areas, the global sales and service organization and the corporate and Group support functions. The Executive Team evaluates the material risks identified in the ERM process and its potential impacts, and decides on actions to mitigate risks and their consequences. The results of the ERM process serve as a key basis in determining the focus areas for Corporate Internal Audit.

Risk assessment

The most relevant risks are presented in Getinge's 2025 Annual Report, meaning that the list does not constitute a complete account of all of the risks to which the Group is exposed. The risks are divided into three categories:

- **External** – risks that cannot be controlled, but that are monitored and prepared for in order to optimize outcomes and turn risks into opportunities.
- **Operational** – Risks that are largely controllable and preventable, mainly related to processes, assets and employees.
- **Strategic** – risks that make it more difficult to achieve the strategic targets. These risks are to be managed by balancing risks and the potential for maximizing advantages.

Assurance

The Board of Directors and CEO assure that the interim report provides a true and fair review of the Parent Company and the Group's operations, position and earnings and describes the material risks and uncertainties faced by the Parent Company and the Group.

Gothenburg, April 21, 2026

Johan Malmquist
Chairman,
AGM-elected Board member

Carl Bennet
Vice Chairman,
AGM-elected Board member

Johan Bygge
AGM-elected Board member

Cecilia Daun Wennborg
AGM-elected Board member

Ulrika Dellby
AGM-elected Board member

Dan Frohm
AGM-elected Board member

Mattias Perjos
President & CEO,
AGM-elected Board member

Malin Persson
AGM-elected Board member

Kristian Samuelsson
AGM-elected Board member

Fredrik Brattborn
Board member
Representative of the Swedish
Metalworkers' Union

Åke Larsson
Board member
Representative of the Swedish
Association of Graduate
Engineers

Consolidated financial statements

Condensed consolidated income statement

SEK M	Note	Jan-Mar 2026	Jan-Mar 2025	Jan-Dec 2025
Net sales	2, 3	7,443	8,320	34,969
Cost of goods sold		-3,837	-4,225	-18,315
Gross profit	2, 3, 4	3,606	4,095	16,654
Selling expenses		-1,430	-1,586	-6,050
Administrative expenses		-1,122	-1,180	-4,587
Research and development costs		-328	-318	-1,452
Acquisition costs		-18	-2	-24
Restructuring costs		-12	-296	-374
Other operating income and expenses		12	-115	-379
Operating profit (EBIT)	3, 4	707	598	3,789
Net financial items	3	-135	-170	-644
Profit after financial items	3	573	428	3,145
Taxes		-170	-124	-869
Net profit for the period		402	304	2,276
Attributable to:				
Parent Company shareholders		401	300	2,258
Non-controlling interests		1	4	17
Net profit for the period		402	304	2,276
Earnings per share, SEK ^{1) 2)}		1.47	1.10	8.29
Weighted average number of shares for calculation of earnings per share (000s)		272,370	272,370	272,370

1) Before and after dilution

2) Attributable to the Parent Company shareholders

Consolidated statement of comprehensive income

SEK M	Jan-Mar 2026	Jan-Mar 2025	Jan-Dec 2025
Net profit for the period	402	304	2,276
Other comprehensive income			
Items that cannot be restated in profit for the period			
Actuarial gains/losses pertaining to defined-benefit pension plans	73	102	165
Tax attributable to items that cannot be restated in profit	-21	-29	-45
Items that can later be restated in profit for the period			
Translation differences	975	-2,430	-4,160
Hedging of net investments	140	-518	-754
Cash flow hedges	8	2	-5
Tax attributable to items that can be restated in profit	-30	106	156
Other comprehensive income for the period, net after tax	1,144	-2,766	-4,643
Total comprehensive income for the period	1,546	-2,462	-2,367
Comprehensive income attributable to:			
Parent Company shareholders	1,545	-2,472	-2,373
Non-controlling interests	1	10	6
Total comprehensive income for the period	1,546	-2,462	-2,367

Condensed consolidated balance sheet

SEK M	Note	March 31 2026	March 31 2025	December 31 2025
Intangible assets		34,656	35,991	33,513
Tangible assets		3,524	3,598	3,469
Right-of-use assets		1,498	1,590	1,470
Financial assets		67	49	34
Deferred tax assets		835	878	792
Total non-current assets		40,579	42,106	39,278
Inventories		6,578	6,650	6,018
Accounts receivable		4,931	5,265	5,782
Other current receivables		1,908	2,046	2,026
Cash and cash equivalents	7	4,020	4,203	3,401
Total current assets		17,437	18,164	17,227
TOTAL ASSETS		58,016	60,270	56,505
Equity		31,040	30,748	29,494
Provisions for pensions, interest-bearing	7	2,300	2,452	2,358
Lease liabilities, long-term	7	1,048	1,145	1,029
Interest-bearing liabilities, long-term	7	7,953	8,118	7,893
Deferred tax liabilities		1,814	1,998	1,754
Other provisions, long-term		460	420	485
Other non-interest-bearing liabilities, long-term		473	1,501	452
Total long-term liabilities		14,049	15,633	13,970
Lease liabilities, current	7	461	450	452
Interest-bearing liabilities, current	7	1,526	1,769	1,510
Other provisions, current		1,592	1,939	1,564
Accounts payable		2,063	2,221	2,118
Other non-interest-bearing liabilities, current		7,286	7,509	7,398
Total current liabilities		12,927	13,888	13,042
TOTAL EQUITY AND LIABILITIES		58,016	60,270	56,505

Changes in equity for the Group

SEK M	Share capital	Other capital provided	Reserves ¹⁾	Retained earnings	Total	Non-controlling interests	Total equity
Opening balance at January 1, 2025	136	6,789	5,752	20,328	33,005	205	33,210
Total comprehensive income for the period	-	-	-2,825	373	-2,452	-10	-2,462
Closing balance at March 31, 2025	136	6,789	2,927	20,701	30,553	195	30,748
Opening balance at January 1, 2025	136	6,789	5,752	20,328	33,005	205	33,210
Total comprehensive income for the period	-	-	-4,752	2,378	-2,373	6	-2,367
Dividend	-	-	-	-1,253	-1,253	-14	-1,267
Transactions with non-controlling interests	-	-	-	50	50	-133	-83
Closing balance at December 31, 2025	136	6,789	1,000	21,504	29,430	64	29,494
Opening balance at January 1, 2026	136	6,789	1,000	21,504	29,430	64	29,494
Total comprehensive income for the period	-	-	1,093	452	1,545	1	1,546
Closing balance at March 31, 2026	136	6,789	2,093	21,957	30,975	65	31,040

1) Reserves pertain to cash flow hedges, hedges of net investments and translation differences.

Condensed consolidated cash flow statement

SEK M	Note	Jan-Mar 2026	Jan-Mar 2025	Jan-Dec 2025
Operating activities				
Operating profit (EBIT)		707	598	3,789
Add-back of depreciation, amortization and write-downs	4	484	566	2,250
Other non-cash items		2	11	164
Add-back of restructuring costs ¹⁾		12	276	362
Paid restructuring costs		-67	-105	-338
Financial items ²⁾		-117	-118	-516
Taxes paid		-157	-95	-574
Cash flow before changes in working capital		864	1,132	5,137
Changes in working capital				
Inventories		-347	-684	-465
Operating receivables		1,171	766	-218
Operating liabilities ³⁾		-582	-744	-504
Cash flow from operating activities		1,106	470	3,949
Investing activities				
Acquisition of operations	9	-	-91	-1,663
Investments in intangible assets and tangible assets		-268	-313	-1,314
Divestment of non-current assets		4	3	17
Cash flow from investing activities		-264	-401	-2,960
Financing activities				
Change in interest-bearing liabilities		-68	1,266	1,000
Depreciation of lease liabilities		-122	-129	-501
Change in long-term receivables		-	-1	3
Dividend paid		-	-	-1,267
Cash flow from financing activities		-189	1,136	-765
Cash flow for the period		653	1,205	224
Cash and cash equivalents at the beginning of the period		3,401	2,961	2,961
Translation differences		-34	37	216
Cash and cash equivalents at the end of the period		4,020	4,203	3,401

1) Excluding write-downs on non-current assets

2) Of which interest paid and received in the quarter amounted to SEK -110 M (-113) and other financial items to SEK -7 M (-5)

Note 1 Accounting policies

The Group's interim report has been prepared in accordance with IAS 34 Interim Financial Reporting and the Swedish Annual Accounts Act. For the Parent Company, the report has been prepared in accordance with the Swedish Annual Accounts Act and RFR 2. The accounting policies adopted are consistent with those applied for the 2025 Annual Report and should be read in conjunction with that Annual Report.

For practical reasons, the figures in this interim report have not been rounded off, which is why notes and tables may not total correct amounts. Unless otherwise specified, all figures pertain to SEK M and figures in parentheses pertain to the year-earlier period. The interim report provides alternative performance measures for monitoring the Group's operations.

Note 2 Net sales

	Jan-Mar 2026	Jan-Mar 2025	Jan-Dec 2025
Net sales, SEK M			
Capital goods	2,078	2,481	11,968
Recurring revenue			
Product sales	3,788	4,150	16,185
Service assignments incl. spare parts	1,577	1,689	6,815
Total recurring revenue	5,365	5,839	23,001
Total	7,443	8,320	34,969

	Jan-Mar 2026	Jan-Mar 2025	Jan-Dec 2025
Net sales, SEK M			
Revenue recognized at a point in time			
Acute Care Therapies	3,745	4,504	17,499
Life Science	828	800	3,386
Surgical Workflows	1,923	2,090	9,626
Total revenue recognized at a point in time	6,496	7,394	30,512
Revenue recognized over time			
Acute Care Therapies			
Service	243	253	1,068
Profit from ongoing projects	1	-	-
Other revenue recognized over time	24	18	108
Total Acute Care Therapies	268	271	1,176
Life Science			
Service	63	63	260
Profit from ongoing projects	111	87	852
Other revenue recognized over time	-	0	0
Total Life Science	175	150	1,112
Surgical Workflows			
Service	454	445	1,870
Profit from ongoing projects	15	29	139
Other revenue recognized over time	36	30	160
Total Surgical Workflows	505	505	2,170
Total revenue recognized over time	947	925	4,457
Total revenue recognized at a point in time and over time	7,443	8,320	34,969

For further information about the distribution of sales for each business area, see pages 6-8.

Note 3 Segment overview

	Jan-Mar 2026	Jan-Mar 2025	Jan-Dec 2025
Net sales, SEK M			
Acute Care Therapies	4,012	4,775	18,675
Life Science	1,003	950	4,498
Surgical Workflows	2,428	2,595	11,796
Total	7,443	8,320	34,969

	Jan-Mar 2026	Jan-Mar 2025	Jan-Dec 2025
Gross profit, SEK M			
Acute Care Therapies	2,305	2,769	10,420
Life Science	351	346	1,556
Surgical Workflows	950	979	4,679
Total	3,606	4,095	16,654

	Jan-Mar 2026	Jan-Mar 2025	Jan-Dec 2025
Operating profit (EBIT), SEK M			
Acute Care Therapies	703	692	3,021
Life Science	80	38	470
Surgical Workflows	52	-21	773
Group functions and other (incl. eliminations) ¹⁾	-128	-112	-474
Operating profit (EBIT)	707	598	3,789
Net financial items	-135	-170	-644
Profit after financial items	573	428	3,145

1) Group functions and other refer mainly to central functions such as finance, communication, HR and other items, such as eliminations.

	Jan-Mar 2026	Jan-Mar 2025	Jan-Dec 2025
Net sales, SEK M			
EMEA	2,635	2,630	12,340
<i>of which, Sweden</i>	<i>151</i>	<i>139</i>	<i>648</i>
Americas	3,453	4,047	15,686
<i>of which, USA</i>	<i>3,138</i>	<i>3,693</i>	<i>14,157</i>
APAC	1,355	1,642	6,943
Total	7,443	8,320	34,969

Note 4 Depreciation, amortization and write-downs

	Jan-Mar 2026	Jan-Mar 2025	Jan-Dec 2025
SEK M			
Acquired intangible assets	-87	-107	-434
Intangible assets	-130	-164	-643
Right-of-use assets	-125	-136	-523
Tangible assets	-142	-159	-650
Total	-484	-566	-2,250
<i>Write-downs included in total</i>	<i>-</i>	<i>-20</i>	<i>-166</i>

	Jan-Mar 2026	Jan-Mar 2025	Jan-Dec 2025
SEK M			
Cost of goods sold	-223	-242	-953
Selling expenses	-153	-181	-705
Administrative expenses	-89	-105	-405
Research and development costs	-19	-17	-175
Restructuring costs	-	-20	-12
Total	-484	-566	-2,250
<i>Write-downs included in total</i>	<i>-</i>	<i>-20</i>	<i>-166</i>

Note 5 Quarterly results

SEK M	Jan-Mar 2026	Oct-Dec 2025	Jul-Sep 2025	Apr-Jun 2025	Jan-Mar 2025	Oct-Dec 2024	Jul-Sep 2024	Apr-Jun 2024
Net sales	7,443	10,186	8,226	8,238	8,320	11,071	7,870	8,305
Cost of goods sold	-3,837	-5,382	-4,411	-4,296	-4,225	-6,018	-4,315	-4,394
Gross profit	3,606	4,803	3,815	3,941	4,095	5,053	3,556	3,911
Operating expenses	-2,899	-3,432	-2,863	-3,074	-3,497	-3,969	-3,372	-3,081
Operating profit (EBIT)	707	1,371	952	867	598	1,084	184	830
Net financial items	-135	-164	-163	-147	-170	-173	-152	-130
Profit after financial items	573	1,207	789	721	428	911	32	700
Taxes	-170	-338	-214	-194	-124	-243	-24	-187
Net profit for the period	402	869	576	527	304	668	8	513

Note 6 Adjustment items

Adjusted EBITA, SEK M	Jan-Mar 2026	Jan-Mar 2025	Jan-Dec 2025
Acute Care Therapies	763	1,012	3,763
Life Science	96	53	490
Surgical Workflows	75	49	1,077
Group functions and other (incl. eliminations)	-110	-110	-450
Total	824	1,003	4,880

Adjustments of EBITA, SEK M	Jan-Mar 2026	Jan-Mar 2025	Jan-Dec 2025
Specification of items affecting comparability that impact EBITA			
Restructuring costs, Acute Care Therapies	-5	-251	-293
Restructuring costs, Life Science	-4	0	-22
Restructuring costs, Surgical Workflows	-4	-45	-59
Write-down of R&D, Acute Care Therapies	-	-	-28
Write-down of R&D, Surgical Workflows	-	-	-107
Increased provision for contingent consideration, Acute Care Therapies ¹⁾	-	-	-179
Dissolution of provisions for contingent consideration, Life Science ¹⁾	-	-	55
Group functions and other (incl. eliminations)	-18	-2	-24
Total	-30	-298	-656

Items affecting comparability per segment	Jan-Mar 2026	Jan-Mar 2025	Jan-Dec 2025
Acute Care Therapies	-5	-251	-500
Life Science	-4	0	33
Surgical Workflows	-4	-45	-166
Group functions and other (incl. eliminations)	-18	-2	-24
Total	-30	-298	-656

1) Reported in Other operating income and operating expenses

EBITA, SEK M	Jan-Mar 2026	Jan-Mar 2025	Jan-Dec 2025
Acute Care Therapies	758	761	3,264
Life Science	92	53	523
Surgical Workflows	71	4	911
Group functions and other (incl. eliminations)	-128	-112	-474
Total	794	705	4,223

Adjustments of EBIT, SEK M	Jan-Mar 2026	Jan-Mar 2025	Jan-Dec 2025
Items affecting comparability that impact EBITA (according to above)	-30	-298	-656
Items affecting comparability that impact EBIT but not EBITA ¹⁾	-	-	-48
Total	-30	-298	-704

1) Write-down of acquired intangible assets, Surgical Workflows. Reported in Operating expenses

Effect of adjustment of tax, SEK M	Jan-Mar 2026	Jan-Mar 2025	Jan-Dec 2025
Amortization and write-down of acquired intangible assets ¹⁾	87	107	386
Items affecting comparability	30	298	704
Adjustment items, total	117	405	1,091

Tax on adjustment items ²⁾	-29	-112	-273
Adjustment for tax items affecting comparability	-	-	-
Total	-29	-112	-273

1) Excluding write-downs classified as items affecting comparability

2) Tax effect on tax deductible adjustment items

Note 7 Consolidated net interest-bearing debt

SEK M	March 31 2026	March 31 2025	December 31 2025
Interest-bearing liabilities, current	1,526	1,769	1,510
Interest-bearing liabilities, long-term	7,953	8,118	7,893
Provisions for pensions, interest-bearing	2,300	2,452	2,358
Lease liabilities, current	461	450	452
Lease liabilities, long-term	1,048	1,145	1,029
Interest-bearing liabilities	13,288	13,934	13,241
Less cash and cash equivalents	-4,020	-4,203	-3,401
Net interest-bearing cash/debt	9,268	9,731	9,840

Note 8 Key figures for the Group

Financial and operative key figures	Jan-Mar 2026	Jan-Mar 2025	Jan-Dec 2025
Key figures based on Getinge's financial targets			
Adjusted earnings per share ¹⁾ , SEK	1.8	2.18	11.29
Growth in adjusted earnings per share ¹⁾ , %	-17.7	13.5	-3.7
Other operative and financial key figures			
Organic growth in order intake, %	3.9	2.9	3.5
Organic growth in net sales, %	0.8	6.2	4.9
Gross margin, %	48.4	49.2	47.6
Selling expenses, % of net sales	19.2	19.1	17.3
Administrative expenses, % of net sales	15.1	14.2	13.1
Research and development costs, gross as a % of net sales	6.5	5.9	6.0
Operating margin, %	9.5	7.2	10.8
EBITDA, SEK M	1,191	1,164	6,039
Average number of shares, thousands	272,370	272,370	272,370
Number of shares at the end of the period, thousands	272,370	272,370	272,370
Interest-coverage ratio, multiple	11.1	12.0	11.2
Net debt/equity ratio, multiple	0.30	0.32	0.33
Net debt/Rolling 12m adjusted EBITDA, multiple	1.5	1.4	1.5
Capital employed, SEK M	40,260	41,365	40,934
Return on capital employed, %	10.8	11.3	11.0
Return on equity, %	7.9	4.7	7.5
Equity/assets ratio, %	53.5	51.0	52.2
Equity per share, SEK	113.96	112.89	108.28
Number of employees	11,754	11,827	11,670

1) Before and after dilution

Alternative performance measures

Alternative performance measures refer to financial measures used by the company's management and investors to evaluate the Group's earnings and financial position and that cannot be directly read or derived from the financial statements. These financial measures are intended to facilitate analysis of the Group's performance. Accordingly, the alternative performance measures should be considered a supplement to the financial statements prepared in accordance with IFRS. The financial measures recognized in this report may differ from similar measures used by other companies.

	Jan-Mar 2026
Calculation of organic net sales	
Net sales Jan-Mar 2025	8,320
<i>Adjustment of:</i>	
Divested operations and products as well as products being phased out, in the comparative period	-59
Net sales Jan-Mar 2025 adjusted for divested operations and products	8,261
Net Sales Jan-Mar 2026	7,443
<i>Adjustment of:</i>	
Currency translation	901
Acquired and divested operations and products	-17
Net sales, organic	8,327

	Jan-Mar 2026	Jan-Mar 2025	R12 Mar 2026	Jan-Dec 2025
Adjusted gross profit, SEK M				
Gross profit	3,606	4,095	16,166	16,654
<i>Add-back of:</i>				
Depreciation, amortization and write-downs of intangible assets and tangible assets	223	242	933	953
Other items affecting comparability	-	-	-	-
Adjustment for write-downs included in other items affecting comparability	-	-	-	-
Adjusted gross profit	3,828	4,337	17,099	17,607

	Jan-Mar 2026	Jan-Mar 2025	R12 Mar 2026	Jan-Dec 2025
Adjusted EBITDA, SEK M				
Operating profit (EBIT)	707	598	3,898	3,789
<i>Add-back of:</i>				
Depreciation, amortization and write-downs of intangible assets and tangible assets	397	459	1,802	1,864
Amortization and write-down of acquired intangible assets	87	107	366	386
Other items affecting comparability	-	-	307	307
Acquisition and restructuring costs	30	298	130	397
Adjustment for write-downs included in other items affecting comparability and restructuring costs	-	-20	-142	-162
Adjusted EBITDA	1,222	1,442	6,361	6,581

	Jan-Mar 2026	Jan-Mar 2025	R12 Mar 2026	Jan-Dec 2025
Adjusted EBITA, SEK M				
Operating profit (EBIT)	707	598	3,898	3,789
<i>Add-back of:</i>				
Amortization and write-down of acquired intangible assets	87	107	366	386
Other items affecting comparability	-	-	307	307
Acquisition and restructuring costs	30	298	130	397
Adjusted EBITA	824	1,003	4,701	4,880

	Jan-Mar 2026	Jan-Mar 2025	R12 Mar 2026	Jan-Dec 2025
Adjusted EBIT, SEK M				
Operating profit (EBIT)	707	598	3,898	3,789
<i>Add-back of:</i>				
Other items affecting comparability	-	-	307	307
Acquisition and restructuring costs	30	298	130	397
Adjusted EBIT	738	896	4,335	4,494

	Jan-Mar 2026	Jan-Mar 2025	R12 Mar 2026	Jan-Dec 2025
Adjusted net profit for the period, SEK M				
Net profit for the period	402	304	2,374	2,276
<i>Add-back of:</i>				
Amortization and write-down of acquired intangible assets	87	107	366	386
Other items affecting comparability	-	-	307	307

Acquisition and restructuring costs	30	298	130	397
Tax items affecting comparability	-	-	-	-
Tax on add-back items	-29	-112	-191	-273
Adjusted net profit for the period	490	597	2,986	3,093

The calculation of adjusted earnings per share, before and after dilution, attributable to Parent Company shareholders, is based on the following information:	Jan-Mar 2026	Jan-Mar 2025	R12 Mar 2026	Jan-Dec 2025
Earnings (numerator), SEK M				
Adjusted net profit for the period	490	597	2,986	3,093
Adjusted net profit for the period attributable to non-controlling interest	-1	-4	-14	-17
Adjusted net profit for the period attributable to the Parent Company shareholders, which forms the basis for calculation of adjusted earnings per share	489	593	2,972	3,076
Number of shares (denominator)				
Weighted average number of ordinary shares for calculation of adjusted earnings per share (thousands)	272,370	272,370	272,370	272,370
Adjusted earnings per share, SEK	1.80	2.18	10.91	11.29

The calculation of adjusted EBITA margin, adjusted for currency impact and tariff costs, is based on the following information:	Jan-Mar 2026
Adjusted EBITA (numerator), SEK M	
Adjusted EBITA	824
Add-back of:	
Currency impact	122
Tariffs costs	104
Adjusted EBITA, adjusted for currency impact and tariff costs	1,050
Net sales (denominator)	
Net sales	7,443
Add-back of:	
Currency impact	901
Net sales, adjusted for currency impact	8,344
Adjusted EBITA margin, adjusted for currency impact and tariff costs, %	12.6

Note 9 Acquisitions

No acquisitions took place during the first quarter that had a material impact on the Group's financial earnings and position.

Contingent considerations

Getinge signed agreements on contingent considerations in connection with acquisitions of assets and subsidiaries. Liabilities for these additional purchase prices are measured at fair value through profit or loss at Level 3 of the fair value hierarchy. The additional purchase prices are contingent on securing government approval for the acquired product development projects and contingent on the earnings performance of the acquired businesses. Future cash flows are discounted if the planned payment date exceeds 12 months. Assessments of future cash flows related to the contingent consideration are regularly reviewed by company management and recognized at fair value. The discount effect is recognized in profit or loss under financial items on an ongoing basis.

	March 31 2026	March 31 2025	December 31 2025
Contingent considerations			
Opening balance	1,444	3,280	3,280
Business combinations	-	-	-
Dissolution of provision	-	-	-55
Fair value adjustments recognized in profit or loss	-	5	184
Payments	-	-110	-1,599
Discount effect	15	31	77
Translation differences	63	-291	-443
Closing balance	1,522	2,915	1,444

Parent Company financial statements

Condensed Parent Company's income statement

SEK M	Jan-Mar 2026	Jan-Mar 2025	Jan-Dec 2025
Net sales	95	107	348
Administrative expenses	-138	-88	-397
Operating profit/loss	-43	19	-49
Result from participations in Group companies ¹⁾	-	-	2,134
Interest income and other similar income ²⁾	5	17	55
Interest expenses and other similar expenses ²⁾	-49	-55	-220
Profit/loss after financial items	-87	-19	1,920
Appropriations	-	-	60
Taxes	9	-4	-24
Net profit/loss for the period³⁾	-78	-23	1,956

1) Primarily refers to dividends from Group companies that take place on an ongoing basis throughout the year

2) Interest income and other similar income and interest expenses and other similar expenses include exchange-rate gains and losses attributable to the translation of financial receivables and liabilities measured in foreign currencies

3) Comprehensive income for the period corresponds to net profit for the period

Condensed Parent Company's balance sheet

SEK M	March 31 2026	March 31 2025	December 31 2025
Assets			
Tangible assets	1	2	1
Participations in Group companies	32,256	29,582	31,572
Deferred tax assets	106	95	97
Current receivables from Group companies	207	1,797	974
Current receivables	27	43	40
Cash and bank balances	0	903	2
Total assets	32,597	32,422	32,687
Equity and liabilities			
Equity	26,294	25,645	26,372
Long-term liabilities	5,394	5,093	5,394
Other provisions	22	20	18
Current liabilities to Group companies	1	1	7
Current liabilities	885	1,663	896
Total equity and liabilities	32,597	32,422	32,687

Definitions

Financial terms

Adjusted earnings per share: Adjusted net profit for the period attributable to Parent Company shareholders in relation to average number of shares.

Adjusted EBIT: Operating profit (EBIT) with add-back of acquisition and restructuring costs and other items affecting comparability.

Adjusted EBITA: EBITA with add-back of acquisition and restructuring costs and other items affecting comparability.

Adjusted EBITDA: EBITDA with add-back of acquisition and restructuring costs and other items affecting comparability.

Adjusted gross profit: Gross profit with add-back of depreciation, amortization and write-downs and other items affecting comparability.

Adjusted net profit for the period: Net profit for the period with add-back of amortization and write-down of acquired intangible assets, acquisition and restructuring costs, other items affecting comparability and tax effect of add-back of income-statement items.

Adjusted profit before tax: Profit before tax for the period with add-back of amortization and write-down of acquired intangible assets, acquisition and restructuring costs and other items affecting comparability.

Capital employed: Average total assets with add-back of cash and cash equivalents, other provisions, accounts payable and other non-interest-bearing liabilities.

Capital goods: Durable products that are not consumed when used.

Currency transaction effect: Exchange of current year's volumes of foreign currency at this year's exchange rates, compared with the exchange rates in the preceding year.

Earnings per share: Net profit attributable to Parent Company shareholders in relation to average number of shares.

EBIT: Operating profit.

EBITA margin: EBITA in relation to net sales.

EBITA: Operating profit (EBIT) before add-back of amortization and write-down of acquired intangible assets.

EBITDA margin: EBITDA in relation to net sales.

EBITDA: Operating profit (EBIT) with add-back of amortization, depreciation and write-downs.

Equity per share: Equity in relation to the number of shares at the end of the period.

Equity/assets ratio: Equity in relation to total assets.

Free cash flow: Cash flow from operating activities and investing activities, excluding acquisitions and divestment of operations.

Gross margin: Gross profit in relation to net sales.

Interest-coverage ratio: Rolling 12 months' adjusted EBITDA in relation to rolling 12 months' net interest.

Items affecting comparability: Acquisition and restructuring costs and other items affecting comparability. Other items affecting comparability are significant revenue/expenses that impact comparability between accounting periods. These items include, but are not limited to, write-downs, disputes and major gains and losses attributable to divestments of assets or businesses.

Net debt/equity ratio: Net interest-bearing debt in relation to equity.

Operating liabilities: Accounts payable, other provisions and other non-interest-bearing liabilities (contract liabilities, non-interest-bearing provisions for pensions and similar obligations, accrued expenses and deferred income as well as other liabilities).

Operating margin: Operating profit (EBIT) in relation to net sales.

Operating receivables: Accounts receivable and other current receivables (contract assets, prepaid expenses and accrued income, and other receivables).

Organic change: A financial change adjusted for currency, acquisitions and divestments of operations.

Adjusted to the following from first quarter of 2026:

A financial change adjusted for currency, acquisitions and divestments of operations and phase-out of product categories.

Recurring revenue: Revenue from sales of products that are continuously consumed as well as service, spare parts and similar items.

Return on capital employed: Rolling 12 months' adjusted EBIT in relation to capital employed.

Return on equity: Rolling 12 months' profit after tax in relation to average equity.

Sustainability terms

Double materiality assessment: The process of identifying an organization's impacts on people and the environment and the sustainability-related financial risks and opportunities for the organization. The results are also used to determine whether a sustainability topic is to be included in the company's sustainability report.

Employee engagement: The engagement score in Getinge's employee survey.

ESRS: European Sustainability Reporting Standards.

Online customer training: The number of training courses held for customers. The total number of times a customer has completed an e-learning course or participated in a training webinar.

REC (Renewable Energy Certificates): Used to certify that electricity was generated from renewable sources.

Scope 1 & 2: Carbon emissions from production (in ton CO₂ equivalents). Scope 1 includes emissions from oil and gas consumption. Emissions from Getinge's vehicle fleet are excluded in the interim report but the amounts for the full-year are presented in the Sustainability Report. Scope 2 includes emissions from electricity, heating and cooling. Emissions from leased premises are excluded in the interim report but the amounts for the full-year are presented in the Sustainability Report.

Scope 3: Includes other indirect emissions, both upstream and downstream in the value chain, arising from activities such as freight transport, purchased goods and services, as well as emissions from the use of products sold.

WRAR (Work Related Accident Rate): The number of work related accidents divided by the number of hours worked, normalized by multiplying by 200,000 hours.

Medical terms

Cardiopulmonary: Pertaining or belonging to both heart and lung.

Cardiovascular: Pertaining or belonging to both heart and blood vessels.

DPTE®-BetaBags: Bag that ensures contamination-free transfer of components.

ECMO: Extracorporeal membrane oxygenation, meaning oxygenation outside the body through a membrane. Put simply, a modified cardiac and respiratory machine that exchanges oxygen and carbon dioxide, like an artificial lung.

Endoscope: Equipment for visual examination of the body's cavities, such as the stomach.

Endovascular: Vascular treatment using catheter technologies.

EVH Endoscopic Vessel Harvesting is a minimally invasive technique for removing blood vessels, for example during coronary artery bypass surgery.

Extracorporeal life support (ECLS): Oxygenation of the patient's blood outside the body (extracorporeal) using advanced medical technology.

Grafts: Artificial vascular implants.

Hemodynamic monitoring: Monitoring the balance between blood pressure and blood flow.

Low temperature sterilization: A device used to sterilize surgical instruments which

cannot be sterilized with high temperature steam. It is mainly used for instruments used in the minimal invasive and robotic surgery.

NAVA: Neurally Adjusted Ventilatory Assist (NAVA) identifies the electric activity that activates the diaphragm and using these signals adapts the ventilation to the patient's respiratory rhythm.

Perfusionist: A healthcare professional who operates the heart-lung machine during surgery.

Stent: A tube for endovascular widening of blood vessels.

Sterilizer: A device to eliminate microorganisms on surgical instruments, usually by high temperature with steam.

Vascular intervention: A medical procedure conducted through vascular puncturing instead of using an open surgery method.

Ventilator: Medical device to help patients breath.

Vessel harvesting: The name of the process for removing blood vessels from the body.

WIS: The product category of washers, isolators and sterilizers.

Geographic areas

Americas: North, South and Central America.

APAC: Asia and Pacific (excluding Middle East).

EMEA: Europe, Middle East and Africa.

Teleconference

A teleconference with President & CEO Mattias Perjos and CFO Agneta Palmér will be held on April 21, 2026 at 1:00–2:00 p.m. CEST.

Fund managers, analysts and the media are invited to the teleconference.

Register via <https://events.inderes.com/getinge/q1-report-2026/dial-in> to participate in the teleconference. After registering, you will receive a telephone number and a conference ID to log in to the teleconference. You can ask questions verbally at the teleconference.

A presentation will be held during the telephone conference. To access the presentation, click on <https://events.inderes.com/getinge/q4-report-2025/dial-in>. A recording will be available via <https://getinge.events.inderes.com/q1-report-2026> for three years.

Financial information

Updated information on, for example, the Getinge share and corporate governance is available on Getinge’s website www.getinge.com. The Annual Report, year-end report and interim reports are published in Swedish and English and are available for download at www.getinge.com. The preliminary dates for financial communication are provided below:

April 21, 2026	Annual General Meeting
July 17, 2026	Q2 Report 2026
October 20, 2026	Q3 Report 2026
January 26, 2027	Q4 and Year-end report 2026

Contact

David Kördel, Head of Investor Relations
 +46 (0)10 335 0077
david.kordel@getinge.com

This information is such that Getinge AB (publ) is obligated to disclose in accordance with the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on April 21, 2026 at 12:00 p.m. CEST.

With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions that aim to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. Getinge employs about 12,000 people worldwide and the products are sold in more than 135 countries.
 Getinge has been listed on Nasdaq OMX Stockholm, Nordic Large Cap since 1993.

Getinge AB (publ) | Lindholmospiren 7A, 417 56 Gothenburg, Sweden | Tel: +46 (0)10 335 0000 | E-mail: info@getinge.com | Corp. Reg. No.: 556408-5032 | www.getinge.com